经营业绩： 重大事项： 上海实业控股(00363)：上海华氏及上实城开上海大健康管理拟7359.8万元出售上海上实医疗美容医院 49%股权 恒瑞医药(01276)：瑞维鲁胺片获得药物临床试验批准通知书 康希诺生物(06185)：吸入用结核病加强疫苗于印度尼西亚启动I期临床试验并完成首例受试者入组 中慧生物-B(02627)：四价流感病毒亚单位疫苗(佐剂)及三价流感病毒亚单位疫苗(佐剂)的I期临床试验启 动 智云健康(09955)与京东健康(06618)订立服务合作协议 拓宽莉芙敏片®及其他P2M管线产品的线上销售 与服务渠道 华润置地(01109)拟配售华润万象生活(01209)股份 推动股东结构多元化 首程控股(00697)：北京机器人基金投资星动纪元 京东健康(06618)发布第三季度业绩 经营盈利12.43亿元 同比增加125.3% 中芯国际(00981)公布第三季度业绩 公司拥有人应占盈利约1.92亿美元 环比增长44.7% 同比增长28.9% 哔哩哔哩-W(09626)第三季度净利润4.69亿元 同比扭亏为盈 各项核心用户指标均创历史新高 中国太保(02601)：太平洋人寿保险前10个月原保险保费收 ...

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has signed a service cooperation agreement with JD Health to expand the online sales and service channels for its products [1] - JD Health is recognized as the largest pharmaceutical e-commerce platform in China, offering a vast user base and extensive platform resources [1] - The partnership represents a strong alliance that will effectively promote high-quality and cost-effective medications [1] Group 2: Company Strengths - Zhiyun Health is a leading platform in chronic disease management, possessing a unique product pipeline and expertise in patient management [1] - The collaboration leverages the strengths of both companies to enhance patient access to medications and health services [1]

Core Viewpoint - The collaboration between Zhiyun Health and JD Health aims to enhance online sales and service channels for Livermore tablets and other P2M pipeline products, providing patients with a more convenient purchasing experience and comprehensive health management services [1] Group 1: Partnership Details - Zhiyun Health has entered into a service cooperation agreement with JD Health, a major player in the Chinese pharmaceutical e-commerce market [1] - The partnership is expected to leverage JD Health's extensive user base and platform resources to promote high-quality and cost-effective medications [1] Group 2: Strategic Implications - This collaboration represents a strong alliance between two leading companies in their respective fields, enhancing the potential for effective promotion of health management solutions [1] - The partnership will facilitate better patient access to medications and health management services, aligning with the growing trend of digital health solutions in China [1]